Moderna announces skin cancer vaccine and shares soar 150%
An experimental mRNA vaccine, developed by Moderna in partnership with Merck, reduced the risk of recurrence and progression of melanoma in high-risk patients, according to results released on Wednesday. Moderna's shares soared and were traded at $161.32 after the announcement, a dizzying intraday high of 158%.
Moderna and Merck have developed an experimental mRNA vaccine that reduced the risk of melanoma recurrence and progression in high-risk patients. The vaccine, called intismeran, was tested in a clinical trial involving 1,137 patients with stage IIB to IV melanoma who had undergone surgical tumor removal. The treatment, which combines the mRNA vaccine with Merck's immunotherapy Keytruda, met its two main objectives, reducing the risk of cancer recurrence and spread to other parts of the body.
Moderna's CEO Stéphane Bancel expects to submit the data to regulatory authorities as soon as possible, with the goal of making the treatment available to patients in 2027.
Written by urgent.news from Brazil Journal's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
